Microbiome transplant to treat vaginal tract dysbiosis clears phase 1 milestone 29-Jun-2023 By Jonathan Smith A microbiome therapeutic developed by the Danish biotech company Freya Biosciences has achieved promising topline results in a phase 1 trial in women with asymptomatic vaginal tract dysbiosis.
Seres secures first approval of oral microbiome product 04-May-2023 By Ben Hargreaves Seres, together with partners Nestle Health Science, receive approval for its microbiome therapeutic to prevent recurrence of C. difficile infection.